Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast cancer patients was introduced in 1998. Although trastuzumab has opened a new avenue to treat patients with HER2-positive breast cancer and other types of cancer, some patients are not responsive or become resista...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!